Clinical trials: Unresectable Locally Advanced NSCLC
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Non-Squamous Non-Small Cell Lung Cancer
A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.
This single arm study will evaluate the feasibility of treatment with 2 dose levels of Avastin in combination with concurrent thoracic radiation and chemotherapy in patients with locally advanced unresectable non-squamous…
- Trial name
- NCT00776698
- Testing
- bevacizumab [Avastin], cisplatin, etoposide
- Where
- 5 sites in Netherlands, United Kingdom
- Volunteers
- 1 people
- Sponsor
- Hoffmann-La Roche
EGFR, NSCLC (Non-small Cell Lung Cancer)
Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC
The subjects of this study are patients with unresectable stage III non-small cell lung cancer (NSCLC) who have EGFR mutations.
- Conditions
- EGFR, NSCLC (Non-small Cell Lung Cancer), Locally Advanced Non-Small Cell Lung Cancer, Radiotherapy
- Trial name
- NCT07742332
- Testing
- Fumetinib combined platinum-based double chemotherapy, Concurrent Radiochemotherapy
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Peng Zhang
Lung Cancer, Non-Small Cell
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
The goal of this clinical trial is to evaluate the safety and tolerability profile of dostarlimab in combination with belrestotug when compared with pembrolizumab and placebo in participants with previously untreated…
- Trial name
- NCT06472076
- Testing
- Dostarlimab, Belrestotug, Pembrolizumab
- Where
- 108 sites in United States, Argentina and 19 more
- Volunteers
- 88 people
- Sponsor
- GlaxoSmithKline
Non-small Cell Lung Cancer
Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC
This study aims to evaluate the 1-year progression free survival (PFS) rate of tislelizumab combined with sitravatinib as assessed by investigators per RECIST 1.1.
- Trial name
- NCT05176925
- Testing
- Tislelizumab, Sitravatinib
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Fudan University
NSCLC
Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)
This study is intended to show whether inhaled chemotherapy can be added to a standard IV chemotherapy regime, to investigate the additional toxicities and to show initial evidence of efficacy of the combination.
- Trial name
- NCT00082472
- Testing
- Doxorubicin HCl Inhalation Solution, Docetaxel, Cisplatin
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Zivena
NSCLC (Non-small Cell Lung Cancer)
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
This study compares the efficacy and safety of AK104 versus Sugemalimab as consolidation therapy in patients with unresectable, locally advanced NSCLC who have not progressed following concurrent or sequential chemoradiotherapy.
- Trial name
- NCT06617416
- Testing
- Cadonilimab (AK104), Sugemalimab
- Where
- China
- Volunteers
- 560 people
- Sponsor
- Akeso
Non-small Cell Lung Cancer
A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)
This is a trial in adult participants with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC) treated with pembrolizumab in combination with platinum doublet chemotherapy and standard thoracic…
- Trial name
- KEYNOTE-799 (NCT03631784)
- Testing
- Pembrolizumab 200 mg, Paclitaxel 45 mg/m^2, Carboplatin AUC6
- Where
- 56 sites in United States, Australia and 8 more
- Volunteers
- 216 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer (NSCLC)
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer…
- Trial name
- SKYSCRAPER-03 (NCT04513925)
- Testing
- Atezolizumab, Tiragolumab, Durvalumab
- Where
- 189 sites in United States, Argentina and 24 more
- Volunteers
- 829 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC
This is a single-arm non-interventional study (NIS) to evaluate the effectiveness, safety and quality of life (QoL) in patients with advanced NSCLC receiving the combination of nab-paclitaxel and carboplatin as first line…
- Trial name
- NEPTUN (NCT02799862)
- Testing
- Nab-Paclitaxel, Carboplatin
- Where
- Germany
- Volunteers
- 408 people
- Sponsor
- iOMEDICO AG
PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
This is a multicenter, randomized, open-label, international, Phase 3 trial to evaluate the efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in participants with locally…
- Trial name
- NCT06635824
- Testing
- Acasunlimab, Pembrolizumab, Docetaxel
- Where
- 247 sites in United States, Argentina and 25 more
- Volunteers
- 191 people
- Sponsor
- Genmab
Neoadjuvant Non-Small Cell Lung Cancer
Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma
The project is a Phase III, randomized, open-label, multicenter study in which approximately 36 patients with unresectable Stage III ALK positive Lung Adenocarcinoma will be randomized 1:1 to receive lorlatinib or…
- Trial name
- NCT06858410
- Testing
- lorlatinib, concurrent/sequential platinum-based chemoradiotherapy
- Volunteers
- 36 people
- Sponsor
- Guangdong Association of Clinical Trials
Non-Small Cell Lung Cancer NSCLC
Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom
This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with locally advanced, unresectable Stage III non-small cell lung cancer receiving durvalumab in…
- Trial name
- CODAK (NCT04667312)
- Testing
- Durvalumab
- Where
- 10 sites in United Kingdom
- Volunteers
- 115 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.
- Trial name
- PROCLAIM (NCT00686959)
- Testing
- Pemetrexed, Cisplatin, Etoposide
- Where
- 133 sites in United States, Argentina and 17 more
- Volunteers
- 598 people
- Sponsor
- Eli Lilly and Company
Locally Advanced Non-Small Cell Lung Cancer
A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy
This is a phase II, open-Label, multi-centre study to determine the efficacy and safety of Camrelizumab plus apatinib in participants with unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), who have not progressed…
- Trial name
- NCT04749394
- Testing
- Camrelizumab, PD-1 monoclonal antibody, Apatinib, VEGFR2 antibody
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Chinese Academy of Medical Sciences
Lung Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as irinotecan, cisplatin, and etoposide work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00616785
- Testing
- cisplatin, etoposide, irinotecan hydrochloride
- Where
- South Korea
- Volunteers
- 41 people
- Sponsor
- Yonsei University
Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor
Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC
The aim of this study is to investigate the efficacy and safety of intercalated combination of erlotinib and radiotherapy for patients with EGFR-mutant, unresectable, locally advanced NSCLC, and to explore a new treatment…
- Trial name
- TREND (NCT03074864)
- Testing
- Erlotinib Hydrochloride
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Guangdong Provincial People's Hospital
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- DENALI-1 (NCT06682793)
- Testing
- A2B395, xT CDx with HLA-LOH assay
- Where
- 10 sites in United States
- Volunteers
- 240 people
- Sponsor
- A2 Biotherapeutics Inc.
Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life.
- Conditions
- Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8
- Trial name
- NCT06265285
- Testing
- Home Health Encounter, Nivolumab, Patient Monitoring
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
NSCLC, Locally Advanced Lung Carcinoma
Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC
The goal of this single arm, phase II clinical trial is to evaluate the efficacy and safety of cadonilimab (AK104) as induction and consolidation therapy in locally advanced/unresectable non-small cell lung cancer (NSCLC)…
- Trial name
- NCT06448910
- Testing
- Cadonilimab (AK104)
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Fudan University